Endocrine glands

advertisement

4. ENDOCRINE GLANDS

Total number of publications:

58

Total number of cases:

1406

Total number of amplifications:

275

4.1

4.1

4.1

4.1

Tumor Loss Amplicon Percentage

(number of cases)

Amplified genes

(studied from the same cases)

Reference

Pituitary tumor, nonfunctioning

NA ?/23 1

PITUITARY TUMOR, SOMATOMAMMOTROPIC (?/4 cases)

Comment:

Amplifications were not determined.

Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA: Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the ''complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas'' (Carney complex). J Clin Endocrinol Metab 2000,

85:3860-3865.

PITUITARY TUMOR, SPORADIC (0/75 cases)

Trautmann K, Thakker RV, Ellison DW, Ibrahim A, Lees PD, Harding B, Fischer C, Popp S, Bartram

CR, Jauch A: Chromosomal aberrations in sporadic pituitary tumors. Int J Cancer 2001, 91:809-814.

Pituitary adenoma 1q21-q23 8 (1/12)

13q14

13q21-q31

7q11

None

8 (1/12)

42 (5/12)

30 (3/10)

0 (0/10)

2

2

2

3

3

4.1

4.1

4.1

4.1

PITUITARY ADENOMA (1/8 cases) amp(7,9)

Rickert CH, Dockhorn-Dworniczak B, Busch G, Moskopp D, Albert FK, Rama B, Paulus W: Increased chromosomal imbalances in recurrent pituitary adenomas. Acta Neuropathol 2001, 102:615-620.

PITUITARY ADENOMA (4/38 cases) amp(5p15.1pter,5q31qter,6p21.1pter,6q25qter,9q22qter,14q22qter,16,19)/amp(19)/amp(19p)/amp(9q3

3qter,19)

Fan X, Paetau A, Aalto Y, Välimäki M, Sane T, Poranen A, Castresana JS, Knuutila S: Gain of chromosome 3 and loss of 13q are frequent alterations in pituitary adenomas. Cancer Genet Cytogenet

2001, 128:97-103.

PITUITARY ADENOMA (?/52 cases)

Comment:

Amplifications were not determined.

Metzger AK, Mohapatra G, Minn YA, Bollen AW, Lamborn K, Waldman FM, Wilson CB, Feuerstein BG:

Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. J Neurosurg 1999, 90:306-314.

PITUITARY CARCINOMA (3/4 cases) amp(1q,3p,8,14)/amp(13q22qter)/amp(9p,13,14,21)

Rickert CH, Scheithauer BW, Paulus W: Chromosomal aberrations in pituitary carcinoma metastases.

Acta Neuropathol 2001, 102:117-120.

4.1 Pituitary tumors: 31 amplifications out of 222 cases

4.2

4.2

4.3

4.3

Adrenocortical adenoma

Benign adrenocortical lesions

None

None

Adrenocortical carcinoma 2p22.2-pter

2q21.3-p22.2

2q22-qter

6q

8p

9p

11q21.1-qter

Adrenocortical carcinoma

17p

17q

18q

22

1p21-p31

1q22-q41

2p21-pter

2qcen-q35

3p

4q25-qter

5p23-p24

6q16-q21

8p

9p23-p24

4p16

5p15

5q13

5q32-qter

8q24

9q32-qter

0 (0/14)

50 (6/12)

8 (1/12)

25 (3/12)

8 (1/12)

25 (3/12)

17 (2/12)

8 (1/12)

42 (5/12)

25 (3/12)

8 (1/12)

58 (7/12)

8 (1/12)

38 (3/8)

50 (4/8)

38 (3/8)

38 (3/8)

38 (3/8)

38 (3/8)

50 (4/8)

50 (4/8)

38 (3/8)

38 (3/8)

38 (3/8)

67 (8/12)

33 (4/12)

33 (4/12)

42 (5/12)

4

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5

4

4

4

4

5

4

4

4

4

4

4

4

4.3

4.3

11p13-p14

11q14-qter

13q12.2-q31

18q

12q13-q14

25 (3/12)

42 (5/12)

17 (2/12)

25 (3/12)

33 (4/12)

5

5

5

5

5

ADRENOCORTICAL CARCINOMA (7/22 cases) amp(1p34.3pter,1q22q25,3p24pter,17q24q25,19q)/amp(7p11.2p14)/amp(19p13.3)/amp(19p13.3)/amp

(19)/amp(19p)/amp(19q13.4)

Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P: Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes

Chromosomes Cancer 2000, 28:145-152.

Adrenocortical tumours, childhood

1p32-pter 18 (2/11) 6

2q21-q32

3pcen-p14

3q13-q26

4q21-q28

6q16-q22

11p13-p14

11q21

13q21-q31

5q34-qter

7p21-pter

7p22

7q33-qter

7q36

9q34

11q12-q13

17q24-qter

19

22q

36 (4/11)

27 (3/11)

27 (3/11)

64 (7/11)

9 (1/11)

27 (3/11)

9 (1/11)

18 (2/11)

9 (1/11)

18 (2/11)

64 (7/11)

46 (5/11)

9 (1/11)

36 (4/11)

36 (4/11)

9 (1/11)

73 (8/11)

18 (2/11)

6

6

6

6

6

6

6

6

6

6

6

6

6

6

6

6

6

6

4.3

4.3

4.3

4.3

Adrenocortical tumors, childhood

18q12

Xp

Xq21-q25

2q22-q33

73 (8/11)

46 (5/11)

46 (5/11)

44 (4/9)

6

6

6

7

4q

6p21.3

9q34

11q13

12q11-q21

13q22-qter

16

56 (5/9)

22 (2/9)

67 (6/9)

11 (1/9)

11 (1/9)

11 (1/9)

11 (1/9)

7

7

7

7

7

7

7

ADRENOCORTICAL TUMOR (3/35 cases) amp(5q32qter,12q13q15)/amp(5p15)/amp(4p15pter,12q12q15,20q)

Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P: Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 2002, 34:48-57.

ADRENOCORTICAL TUMOR (?/32 cases)

Comment:

Amplifications were not determined.

Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P, Magarey CJ, Russell

CFJ, Schulte K-M, Roher H-D, Delbridge L, Robinson BG: Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 2002, 87:3467-3474.

ADRENOCORTICAL TUMOR, CHILDHOOD

ADDITIONAL LITERATURE

Figueiredo BC, Ribeiro RC, Zambetti G, Haddad B, Pianovsky MD, Pereira RM, DeLacerda L, Sandrini

R: Amplification of 9q34 in childhood adrenocortical tumors: a specific feature unrelated to ethnic origin or living conditions. Braz J Med Biol Res 2000, 33:1217-1224.

4.3 Adrenocortical carcinoma: 66 amplifications out of 129 cases

4.4

4.4

Pancreatic adenocarcinoma

1p32-p34 4 (1/27) 8

1cen-p32

4q31.1-pter

6q

6q21

6q24

9p21.1-22

9p22-pter

9p23-pter

9cen-p21

13q22-32

17p

18p

18q

18q23

Y

6q24

7q22

12p13

22

50 (3/6)

50 (3/6)

23 (3/13)

15 (4/27)

11 (3/27)

4 (1/27)

4 (1/27)

15 (4/27)

50 (3/6)

30 (8/27)

23 (3/13)

4 (1/27)

11 (3/27)

23 (3/13)

23 (3/13)

42 (8/19)

11 (3/27)

7 (2/27)

50 (3/6)

CMYB

9

8

10

8

8

10

10

9,10

9

9

10

8

8

8,11

8

8

8

8

9

PANCREATIC ADENOCARCINOMA (7/8 cases) amp(8q,10q,15q21qter,22)/amp(8q24qter,15q24qter,20q12qter)/amp(1q12qter,3q25q27,6p21.1p22,7p1

3pter,8p23pter)/amp(1q32qter,8p23pter,16p,16q23qter,20q13.1qter)/amp(8q24qter,Xq26qter)/amp(7p,7 q11.2q22,16q,20q)/amp(7p,7q11.2q21,8q23qter,11,14q21qter,16,20)

Armengol G, Knuutila S, Lluis F, Capella G, Miro R, Caballin MR: DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer

Genet Cytogenet 2000, 116:133-141.

4.4

4.4

4.4

4.4

PANCREATIC ADENOCARCINOMA, DUCTAL (?/33 cases)

Comment:

Number of cases was not clearly defined, but high-level amplifications were observed at 5p,

8q13q24.1, 8q22qter, 12p11.2p12, 19q12q13.2, and 20q.

Schleger C, Arens N, Zentgraf H, Bley U, Verbeke C: Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization. J Pathol

2000, 191:27-32.

Pancreatic cancer

6q

9cen-p21

17p

18p

18q

None 0 (0/24)

23 (3/13)

23 (3/13)

23 (3/13)

23 (3/13)

31 (4/13)

10

10

10

10

10

10

PANCREATIC CANCER (?/27 cases)

Comment:

Number of cases was not clearly defined, but amplifications were found at 3q26.3qter, 5p,

7q21q31, 8q, 8q22.1qter, 11q14.1q23.3, 12p11.2pter, 19q13.1qter, 20p11.2pter, and 20q12qter.

Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, Ohmura R, Noguchi T, Iida

Y, Akiyama T, Oga A, Fukumoto Y, Furuya T, Kawauchi S, Sasaki K: A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 2001, 60:151-161.

PANCREATIC CANCER (?/32 cases)

Comment:

Number of cases was not clearly defined, but amplifications were found at 1q12qter,

1q31qter, 1p22.3pter, 2q23qter, 2p23p24, 3q23qter, 3q24qter, 5p, 6q, 7,7q21.1q31.2, 8q11.21qter,

8q22.1qter, 8q24, 11q13.1q14.1, 11q13.3q23.3, 12p, 14q, 15q, 18q11.2pter, 19q13, 20q11.2qter, 20,

22q11.2qter, Xp11.21pter, Xq13qter, and Xq25q28.

Harada T, Okita K, Shiraishi K, Kusano N, Furuya T, Oga A, Kawauchi S, Kondoh S, Sasaki K:

Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction.

Oncology 2002, 62:251-258.

4.4

4.4

4.4

PANCREATIC CARCINOMA (12/20 cases) amp(8q,Xq25qter)/amp(3q24qter,8q22qter,11q13q23,12q22qter)/amp(5p,12p11p12,13q14q32)/amp(8q

)/amp(1q24qter,2q21q34)/amp(12p12pter,15q24qter)/amp(5p12p14,5q14q23,7p,8q)/amp(8q)/amp(20q)

/amp(5p11p14,18p)/amp(12p)/amp(5p)

Harada T, Okita K, Shiraishi K, Kusano N, Kondoh S, Sasaki K: Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res 2002,

62:835-839.

PANCREATIC CARCINOMA, ACINAR (?/6 cases)

Comment

: Amplifications were not determined.

Taruscio D, Paradisi S, Zamboni G, Rigaud G, Falconi M, Scarpa A: Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. Genes

Chromosomes Cancer 2000, 28:294-299.

Pancreatic tumor, endocrine

1p21-p22

1qcen-q22

21 (9/44)

16 (7/44)

12

2q23-q36

3qcen-q21

3q22-q26

4pcen-p14

4q13.3-q24

6q21-q22

8q21.3-qter

9p22-pter

10p13-pter

10q22-q25

11p13

11q14-q22

13q21.1

13q22-q31

15q24-qter

16p

21 (9/44)

25 (11/44)

27 (12/44)

7 (3/44)

7 (3/44)

39 (17/44)

23 (10/44)

9 (4/44)

18 (8/44)

23 (10/44)

30 (13/44)

34 (15/44)

16 (7/44)

16 (7/44)

14 (6/44)

7 (3/44)

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

4.4 Pancreatic tumor, endocrine

16q21-q22

21q21

22q12-qter

Xp22

Xq22-q23

1p22-p31

None

9 (4/44)

18 (8/44)

9 (4/44)

18 (8/44)

25 (11/44)

0 (0/44)

13 (3/23)

1q32-q44

6q15-q22

8q11.2

8q23

11p14-p15.3

11q21-q22

13q21-q31

18q12-q23

5

13 (3/23)

4 (1/23)

22 (5/23)

7p11.2-q11.2 4 (1/23)

7p11.2-q31

7

4 (1/23)

9 (2/23)

9p12-q21

17 (4/23)

17 (4/23)

4 (1/23)

9p13-q34

9q11-q12

9q32-qter

12p11.2-q13

12

16

17p11.2-q25

17

19

20p11.2-q13

20q11-q13

4 (1/23)

4 (1/23)

4 (1/23)

26 (6/23)

35 (8/23)

4 (1/23)

4 (1/23)

13 (3/23)

4 (1/23)

4 (1/23)

35 (8/23)

13 (3/23)

48 (11/23)

9 (2/23)

9 (2/23)

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

12

12

12

12

12

12

13

4.4

4.4

4.4

4.4

4.4

X

21q22 4 (1/23)

26 (6/23)

13

13

PANCREATIC TUMOR, ENDOCRINE (?/93 cases)

Comment:

Amplifications were not determined

Barghorn A, Speel EJM, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth

P: Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 2001, 158:1903-1911.

PANCREATIC TUMOR, ENDOCRINE (0/38 cases: 28 functioning and 10 nonfunctioning endocrine pancreatic tumors)

Speel EJM, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU, Komminoth P:

Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9q34 is an early event in insulinomas. Cancer Res 2001, 61:5186-5192.

PANCREATIC TUMOR, ENDOCRINE (0/45 cases: 17 primary metastatic and 28 nonmetastatic)

Zhao J, Moch H, Scheidweiler AF, Baer A, Schäffer AA, Speel EJM, Roth J, Heitz PU, Komminoth P:

Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer

2001, 32:364-372.

ENTEROPANCREATIC TUMOR, NEUROENDOCRINE (0/26 cases: 12 foregut tumours and 14 midgut tumours)

Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B: Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut

2001, 48:536-541.

PANCREATIC CANCER

ADDITIONAL LITERATURE

Armengol G, Capella G, Farre L, Peinado MA, Miro R, Caballin MR: Genetic evolution in the metastatic progression of human pancreatic cancer studied by CGH. Lab Invest 2001, 81:1703-1707.

4.4 PANCREATIC ADENOCARCINOMA, DUCTAL

ADDITIONAL LITERATURE

Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U: c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol

2002, 15:462-469.

4.4 Pancreatic adenocarcinoma: 149 amplifications out of 446 cases

4.5

4.5

Gastroenteropancreatic endocrine tumor

Bile duct carcinoma, primary

6q16-qter

8p

18q21-qter

17q11

19q13

3q

5 (1/20)

5 (1/20

13 (1/8)

8q21.1-qter

8q

11

12p

13q

17q11.1-q21

38 (3/8)

38 (3/8)

13 (1/8)

38 (3/8)

13 (1/8)

13 (1/8)

25 (2/8)

13 (1/8)

50 (4/8)

14

14

15

15

15

15

15

15

15

15

15

15

4.5 Gastroenteropancreatic tumor: 12 amplifications out of 28 cases

4.6

4.6

4.7

4.7

4.7

4.7

4.7

Thyroid adenoma

Thyroid adenoma, follicular

(22)

None None

7 (2/29) 16

18

Thyroid carcinoma, follicular

1p

31 (4/13) 16

22

13q21-q22

14q11.2-q22

18q12.1-q21

14q11.2-q22

18q12.1-q21

5 (1/20)

5 (1/20)

46 (6/13)

25 (5/20)

5 (1/20)

5 (1/20)

40 (8/20)

17

17

16

17 Thyroid carcinoma, follicular

1p21-p22

9q13-q21.3

22q12.3-qter

20 (4/20)

23 (3/13)

18

17

17

17

17

18

17 Thyroid carcinoma, papillary

None

None 0 (0/26)

THYROID CARCINOMA, PAPILLARY (1/25 cases) amp(1q25qter)

Kjellman P, Lagercrantz S, Hoog A, Wallin G, Larsson C, Zedenius J: Gain of 1q and loss of 9q21.3q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes

Cancer 2001, 32:43-49.

THYROID CANCER, PAPILLARY (0/21 cases)

Singh B, Lim D, Cigudosa JC, Ghossein R, Shaha AR, Poluri A, Wreesmann VB, Tuttle M, Shah JP,

Rao PH: Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Surgery 2000, 128:888-894.

4.7

4.7

4.7

4.7

THYROID CANCER, PAPILLARY (?/17 cases)

Comment:

Amplifications were not determined.

Bauer AJ, Cavalli LR, Rone JD, Francis GL, Burch HB, Tuttle RM, Ringel MD, Stratakis CA, Haddad

BR: Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis. Cancer Genet Cytogenet 2002, 135:182-186.

THYROID CARCINOMA, ANAPLASTIC (?/9cases)

Comment:

Amplifications were not determined, but FISH indicated amp(8q21,5p12) in some cases.

Wilkens L, Benten D, Tchinda J, Brabant G, Potter E, von Wasielewski RHD: Aberrations of chromosomes 5 and 8 as recurrent cytogenetic events in anaplastic carcinoma of the thyroid as detected by fluorescence in situ hybridisation and comparative genomic hybridisation. Virchows Arch

2000, 436:312-318.

THYROID CARCINOMA, MEDULLARY (0/23 cases)

Frisk T, Zedenius J, Lundberg J, Wallin G, Kytola S, Larsson C: CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome. Int J Oncol 2001, 18:1219-

1225.

THYROID CANCER (?/42 cases: 15 WDTC, 12 PDTC, 15ATC)

Comment:

Number of cases not clearly defined, but amplifications were found at 3p14q13, 3q23q25, and 17q24q25.

Wreesmann BV, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle MR, Shah JP,

Rao PH, Singh B: Genome-wide appraisal of thyroid cancer progression. Am J Pathol 2002, 161:1549-

1556.

4.7 Thyroid carcinoma: 10 amplifications out of 196 cases

4.8

4.8

Thyroid oncocytic tumors,

Hürthle cell

None 0 (0/11) 19

Not determined

HÜRTHLE CELL THYROID CARCINOMA (?/28 cases)

Comment:

Amplifications were not determined.

19

Wada N, Duh QY, Miura D, Brunaud L, Wong MG, Clark OH: Chromosomal aberrations by comparative genomic hybridization in Hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin

Endocrinol Metab 2002, 87:4595-4601.

4.9

4.10

4.11

Medullary carcinoma

Anaplastic carcinoma

Parathyroid adenoma

1p

6q26-qter

11p

11cen-q22

11q23-qter

13cen-q12

13q14-qter

15q14-25

15q26

None

None

None

4

5

14q

0 (0/10)

0 (0/13)

0 (0/63)

11 (6/53)

10 (1/10)

10 (1/10)

11 (6/53)

25 (13/53)

30 (16/53)

34 (18/53)

11 (6/53)

17 (9/53)

10 (1/10)

15 (8/53)

13 (7/53)

17

17

20,21

20

21

21

20

20

20

20

20

20

21

20

20

4.11

4.11

4.11

4.11

4.11

PARATHYROID ADENOMA (1/44 cases) amp(7q21q35,8p12p22,8q21.2qter)

Hemmer S, Wasenius V-M, Haglund C, Zhu Y, Knuutila S, Franssila K, Joensuu H: Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol 2001,

158:1355-1362.

PARATHYROID CARCINOMA (?/29 cases)

Comment:

Amplifications were not determined.

Kytölä S, Farnebo F, Obara T, Isola J, Grimelius L, Farnebo L-O, Sandelin K, Larsson C: Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 2000, 157:579-586.

Parathyroid adenoma, 1p34-pter 19 (5/26) sporadic

22

11

15q15-qter

18q

Not determined

39 (10/26)

27 (7/26)

12 (3/26)

22

22

22

22

PARATHYROID ADENOMA, SPORADIC (0/14 cases)

García JL, Tardío JC, Gutiérrez NC, González MB, Polo JR, Hernández JM, Menárguez J:

Chromosomal imbalances identified by comparative genomic hybridization in sporadic parathyroid adenomas. Eur J Endocrinol 2002, 146:209-213.

Parathyroid adenoma, irradiation associated

1pcen-p22

1p32

30 (3/10)

40 (4/10)

22

6q16-q26

11p12-p14

11q

18q

22q

30 (3/10)

40 (4/10)

50 (5/10)

30 (3/10)

30 (3/10)

22

22

22

22

22

22

4.11

4.11

PARATHYROID TUMORS, MULTIPLE (0/5 cases)

Dwight T, Nelson AE, Theodosopoulos G, Richardson AL, Learoyd DL, Philips J, Delbridge L,

Zedenius J, Teh BT, Larsson C, Marsh DJ, Robinson BG: Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J

Pathol 2002, 161:1299-1306.

PARATHYROID TUMORS (?/12 cases)

Comment:

Amplifications were not determined.

Dwight T, Kytölä S, Teh BT, Theodosopoulos G, Richardson AL, Philips J, Twigg S, Delbridge L, Marsh

DJ, Nelson AE, Larsson C, Robinson BG: Genetic analysis of lithium-associated parathyroid tumors.

Eur J Endocrinol 2002, 146:619-627.

4.11 Parathyroid adenoma: 6 amplifications out of 213 cases

4.12 MULTIPLE ENDOCRINE NEOPLASM (?/5 cases)

Comment:

Amplifications were not determined.

Pourani J, Kaserer K, Pfragner R: Cytogenetic and molecular analyses of multiple endocrine neoplasias of the MEN1 syndrome. Int J Oncol 2002, 20:971-976.

4.13

4.14

Thymoma, medullary None None 23

Thymic carcinoma, welldifferentiated, type B3 thymoma

6q 38 (6/16) 23

4.14 Thymic squamous cell carcinoma, primary, type

C thymoma

13q21-q32

6q

8p12 6 (1/16)

31 (5/16)

44 (4/9)

23

23

23

16q13-q24 67 (6/9) 23

17p13 33 (3/9)

23

Concerning Losses:

10% of the cases must be aberrant and the number of aberrant cases at least three; findings in parentheses are examples of highly frequent aberrations that fail to meet the 3 cases/10% criteria; Boldface indicates that more than 30% of the cases detected in a study of at least 10 cases were aberrant;

*

Description of a region, e.g. 6q21-q22, implies that in a variety of cases the loss was located within the area but it did not necessarily affect the whole area in all cases. The described regions may therefore not be considered analogous with minimal overlapping area. Furthermore, in some single cases the loss area may extend beyond the region described. As a whole, the description should be considered a flexible way to summarize critical areas of recurrent DNA copy number changes in that particular tumor type. Description without an asterisk indicates minimal overlapping areas.

Concerning Amplicons:

Boldface indicates recurrent established amplicons (at least three cases and frequency more than 5%).

REFERENCES

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

Daniely M, Aviram A, Adams EF, Buchfelder M, Barkai G, Fahlbusch R, Goldman B, Friedman E:

Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. J Clin Endocrinol Metab 1998,

83:1801-1805.

Harada K, Nishizaki T, Ozaki S, Kubota H, Harada K, Okamura T, Ito H, Sasaki K: Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization. Cancer Genet Cytogenet 1999, 112:38-

41.

Hui ABY, Pang JCS, Ko C-W, Ng H-K: Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization. Hum Pathol 1999, 30:1019-1023.

Kjellman M, Kallioniemi OP, Karhu R, Höög A, Farnebo LO, Auer G, Larsson C, Bäckdahl M: Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 1996, 56:4219-4223.

Zhao J, Speel EJM, Muletta-

Feurer S, Rütimann K, Saremaslani P, Roth J, Heitz PU, Komminoth P: Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 1999, 155:1039-1045.

James LA, Kelsey AM, Birch JM, Varley JM: Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br J Cancer 1999, 81:300-304.

Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovsky MAD, Giatzakis C, Young HM, Haddad

BR: Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol

Metab 1999, 84:1116-1121.

Solinas-

Toldo S, Wallrapp C, Müller-Pillasch F, Bentz M, Gress T, Lichter P: Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 1996, 56:3803-3807.

Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A: Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes

Chromosomes Cancer 1997, 19:161-169.

Mahlamäki EH, Höglund M, Gorunova L, Karhu R, Sawiskiba S, Andrén-Sandberg Å, Kallioniemi O-P,

Johansson B: Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer 1997, 20:383-391.

Wallrapp C, Müller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, Büchler M, Fink T, Adler G, Gress TM:

Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res 1997, 57:3135-3139.

Speel EJM, Richter J, Moch H, Egenter C, Saremaslani P, Rütimann K, Zhao J, Barghorn A, Roth J, Heitz

PU, Komminoth P: Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999, 155:1787-1794.

13.

14.

Stumpf E, Aalto Y, Höög A, Kjellman M, Otonkoski T, Knuutila S, Andersson LC: Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 2000, 29:83-87.

Terris B, Meddeb M, Marchio A, Danglot G, Fléjou J-F, Belghiti J, Ruszniewski P, Bernheim A: Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes

Chromosomes Cancer 1998, 22:50-56.

15. Rijken AM, Hu J, Perlman EJ, Morsberger LA, Long P, Kern SE, Hruban RH, Yeo CJ, Griffin CA: Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes

Chromosomes Cancer 1999, 26:185-191.

16. Hemmer S, Wasenius V-M, Knuutila S, Joensuu H, Franssila K: Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization. Br J Cancer 1998, 78:1012-1017.

17. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H: DNA copy number changes in thyroid

18. carcinoma. Am J Pathol 1999, 154:1539-1547.

Frisk T, Kytölä S, Wallin G, Zedenius J, Larsson C: Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. Genes Chromosomes Cancer 1999,

25:349-353.

19. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC: Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest

1999, 79:547-555.

20. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RSK, Arnold A: Novel chromosomal abnormalities

21.

22. identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocr Metab 1998,

83:1766-1770.

Agarwal SK, Schröck E, Kester MB, Burns AL, Heffess CS, Ried T, Marx SJ: Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 1998, 106:30-36.

Farnebo F, Kytölä S, Teh BT, Dwight T, Wong FK, Höög A, Elvius M, Wassif WS, Thompson NW, Farnebo L-

23.

O, Sandelin K, Larsson C: Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol

Metab 1999, 84:3775-3780.

Zettl A, Ströbel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, Peters K, Krein A, Semik M, Müller-

Hermelink H-K, Marx A: Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000,

157:257-266.

Download